To homepage
820К+ patients have got assistance since 2014
50 countries
1,500 clinics
6K+ reviews
3K+ qualified doctors

What's the Cost of Сarcinomatosis Diagnosis and Treatment in China?

The price is provided on request
ChinaTurkeyAustria
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)from $22,500from $22,500from $40,000
Data verified by Bookimed as of June 2026, based on patient requests and official quotes from 64 clinics worldwide. Median costs are based on real invoices (2025–2026) and updated monthly. Actual prices may vary.

Your Benefits and Guarantees with Bookimed

Transparent Prices & Flexible Installments

No hidden fees – just official clinic prices. Pay at the clinic for Сarcinomatosis treatment and use a flexible installment plan if needed.

Verified Clinics & Doctors Only

Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Сarcinomatosis treatment and have the necessary licenses to serve international patients worldwide.

Free 24/7 Assistance

Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Сarcinomatosis treatment journey.

Why we?

Your personal Bookimed medical coordinator

  • Supports you at every stage
  • Helps choose the right clinic and doctor
  • Ensures quick and convenient access to information

Best Сarcinomatosis Treatment Centers in China: 1 Verified Option and Prices

The Bookimed clinic ranking is based on data science algorithms, providing a trusted, transparent, and objective comparison. It takes into account patient demand, review scores (both positive and negative), the frequency of updates to treatment options and prices, response speed, and clinic certifications.

Get a Medical Assessment for Сarcinomatosis in China: Consult with Experienced Doctors Now

View all Doctors
verified

Liu Shi Xin

40 years of experience

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

verified

Niu Lizhi

30 years of experience

The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.

Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.

Share this content

Video Stories from Bookimed Patients

Dayana
I combined my vacation in Antalya with a check-up.
Procedure: Female check-up
Igor
It was great! Transfers, accommodation, treatment—all included.
Procedure: Dental Implant
Marina
Bookimed did everything for me. I didn't have to worry about anything.
Procedure: Female check-up
Updated: 05/27/2022
Authored by
Anna Leonova
Anna Leonova
Head of Content Marketing Team
A certified medical writer with 10+ years of experience, developed Bookimed’s trusted content, backed by a Master’s in Philology and medical expert interviews worldwide.
Fahad Mawlood
Medical Editor & Data Scientist
General practitioner. Winner of 4 scientific awards. Served in Western Asia. Former Team Leader of a medical team supporting Arabic-speaking patients. Now responsible for data processing and medical content accuracy.
Fahad Mawlood Linkedin
This page may feature information relating to various medical conditions, treatments, and healthcare services available in different countries. Please be advised that the content is provided for informational purposes only and should not be construed as medical advice or guidance. Please consult with your doctor or a qualified medical professional before starting or changing medical treatment.

Expert Overview about Сarcinomatosis Treatment in China

These FAQs come from real patients seeking medical assistance through Bookimed. Answers are given by experienced medical coordinators and trusted clinic representatives.

What is the primary medical protocol used to treat carcinomatosis in China?

China utilizes cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy as the primary protocol for carcinomatosis. The procedure involves removing visible tumors before circulating heated medicine into the abdominal cavity. This integrated approach often combines Western surgical standards with traditional therapies to manage side effects and inflammation.

  • Surgical resection: Surgeons remove all macroscopic tumor masses from the abdominal lining.
  • Thermal perfusion: Chemotherapy heated to approximately 41°C–43°C targets microscopic cancer cells.
  • Patient selection: Candidates typically require a Karnofsky Performance Status score exceeding 70.
  • Disease burden: Protocols generally recommend surgery for patients with peritoneal cancer index scores under 20.

Bookimed Expert Insight: Chinese oncology clinics like Fuda Cancer Hospital offer alternatives to standard systemic chemotherapy. These centers specialize in combining hyperthermic treatments with over 10 types of minimally invasive therapies. This approach is useful for patients seeking options beyond traditional aggressive resection. Accreditation by Joint Commission International ensures these facilities follow standardized protocols for international patients from over 100 countries.

Patient Consensus: Patients emphasize that this aggressive surgery is not a universal solution for everyone. Success depends heavily on receiving a second opinion to verify disease burden and primary tumor type.

Which medical centers in China specialize in peritoneal carcinomatosis?

Beijing Shijitan Hospital and Fuda Cancer Hospital lead Chinas treatment for peritoneal carcinomatosis. These centers utilize cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Specialized teams manage advanced abdominal malignancies. JCI-accredited facilities often provide integrated multi-modal care for international patients.

  • Specialized techniques: Clinics utilize HIPEC, PIPAC, and microwave hyperthermia for peritoneal spread.
  • Leading institution: Beijing Shijitan Hospital holds official recognition from international peritoneal oncology groups.
  • Advanced procedures: Specialists perform cytoreductive surgery for gastric, colorectal, and ovarian cancers.
  • Accreditation standards: Fuda Cancer Hospital maintains JCI accreditation for late-stage cancer treatment.

Bookimed Expert Insight: China is a unique destination for late-stage abdominal cancers. Centers like Fuda Cancer Hospital have served over 30,000 international patients. Clinical teams often accept advanced cases that other global institutions may decline. This high volume allows surgeons to maintain proficiency in complex debulking procedures.

Patient Consensus: Patients note that Chinese doctors often consider surgery for cases deemed inoperable elsewhere. It is important to provide full pathology reports and PET scans before travel.

Is Traditional Chinese Medicine integrated into carcinomatosis care?

Traditional Chinese Medicine (TCM) is integrated into carcinomatosis care strictly as a supportive therapy. Chinese oncology centers combine herbal formulas and acupuncture with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). This integrative approach aims to reduce fluid buildup and alleviate chemotherapy side effects. TCM never replaces surgical or interventional treatments.

  • Ascites management: Herbal injections may reduce abdominal fluid when paired with conventional HIPEC protocols.
  • Symptom relief: Acupuncture and moxibustion help manage nausea, vomiting, and cancer-related fatigue.
  • Immune support: Adjuvant formulas help regulate the immune environment during aggressive chemotherapy cycles.
  • Functional status: Integrated care focuses on improving the patient ability to perform daily activities.

Bookimed Expert Insight: Data shows leading facilities like Fuda Cancer Hospital emphasize minimally invasive technologies over traditional chemo. They utilize NanoKnife and cryosurgery alongside supportive care for advanced stages. This suggests that in China, the value of TCM lies in helping patients physically tolerate these high-tech interventions. Integrating TCM within JCI-accredited hospitals ensures better safety than using standalone alternative clinics.

Patient Consensus: Patients note that integrated hospital teams are more trustworthy for managing herb-drug interactions. They highlight the importance of using TCM specifically for appetite and comfort rather than seeking it as a primary cure.

Does China use proprietary technology for HIPEC delivery?

Chinese oncology centers utilize domestically developed, proprietary platforms like the BR-TRG series for HIPEC delivery. These advanced systems function as high-precision thermal perfusion units. They maintain intra-abdominal temperatures at a precise 43.0°C. This level of control optimizes chemotherapy effectiveness while protecting healthy tissue.

  • Precision monitoring: Proprietary sensors maintain thermal stability within 0.1°C during perfusion.
  • Minimally invasive options: Ultrasound-guided percutaneous delivery treats malignant ascites without full surgery.
  • Advanced drug delivery: Specialized peristaltic pumps convert chemotherapy into micro-droplets for better coverage.
  • Enhanced protocols: Centers often utilize multi-session dense schedules over several days.

Bookimed Expert Insight: While Chinese manufacturers dominate the domestic market, the real differentiator is clinical volume. Fuda Cancer Hospital has served over 30,000 international patients. This high volume allows surgeons to master proprietary tools like microwave hyperthermia. This experience often leads to more refined, personalized perfusion protocols than standard settings.

Patient Consensus: Patients note it is vital to confirm if a clinic performs full cytoreductive surgery alongside HIPEC. Many emphasize asking for specific data on surgeon volume and perfusion temperatures rather than just focusing on the machine brand.

Are advanced biological or targeted therapies offered beyond CRS-HIPEC?

Oncology centers in China offer biological and targeted therapies alongside CRS-HIPEC for peritoneal carcinomatosis. These include PARP inhibitors for ovarian cancer and angiogenesis inhibitors like Bevacizumab. Specialized facilities often integrate immunotherapy with minimally invasive technologies. Procedures like PIPAC provide localized delivery for unresectable cases.

  • Systemic targeted drugs: Olaparib and Niraparib provide maintenance after surgery for BRCA-mutated cases.
  • Angiogenesis inhibitors: Bevacizumab targets blood vessel growth to manage colorectal and ovarian spread.
  • Immune checkpoint inhibitors: Medications like Nivolumab treat mismatch repair-deficient (dMMR) or MSI-H cancers.
  • Localized aerosol delivery: PIPAC uses pressure to increase chemotherapy penetration during laparoscopic procedures.
  • Advanced thermal therapies: Specialized centers utilize microwave hyperthermia to treat carcinomatosis at any stage.

Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital treat over 30,000 international patients. They often combine standard HIPEC with unique techniques like NanoKnife and cryosurgery. This multi-modal approach helps manage late-stage cases that are often ineligible for surgery. Specialists like Prof. Liu Shi Xin emphasize precision radiotherapy for abdominal malignancies alongside systemic drugs.

Patient Consensus: Patients note that targeted therapy isn't automatic and requires specific genetic testing for mutations like KRAS or HER2. Many advise confirming if a center has integrated medical oncology teams before starting treatment.

Can international patients receive carcinomatosis treatment in China?

International patients receive carcinomatosis treatment in China at JCI-accredited oncology centers and university hospitals. These facilities specialize in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Treatment integrates Western surgical protocols with advanced ablation technologies like NanoKnife to target solid tumor metastases.

  • Treatment approaches: Clinics utilize cytoreductive surgery paired with heated intraperitoneal chemotherapy protocols.
  • Advanced technologies: Specialized centers offer NanoKnife, cryosurgery, and microwave hyperthermia for stage 4 cases.
  • Radiation techniques: Modern systems provide precision VMAT, IMRT, and SBRT for abdominal malignancies.
  • Clinical volume: Leading hospitals like Fuda have treated 30,000 patients from 100 countries.

Bookimed Expert Insight: China offers a unique advantage for patients with specific solid tumor markers because it leads in CAR-T therapy trials for gastric and colorectal carcinomatosis. Hospitals like Xiamen Humanity Hospital utilize elite experts like Dr. Liu Shi Xin, who holds a State Council Special Government Allowance for oncology. Patients should prioritize clinics with dedicated peritoneal surface oncology departments rather than general cancer wards.

Patient Consensus: Patients emphasize the need for medical records to be pre-reviewed by Chinese surgical teams before traveling. They note that having on-site English-speaking coordinators and translators is vital for understanding pathology results and post-operative instructions.

Who is involved in making the final treatment decisions?

Final treatment decisions for carcinomatosis in China result from shared decision-making between patients, families, and multidisciplinary medical teams. While competent adults maintain the legal right to consent, cultural norms often prioritize family consensus. Clinical experts provide specialized guidance on complex interventions like HIPEC or NanoKnife surgery.

  • Patient authority: Competent individuals hold the final ethical right to accept or refuse medical interventions.
  • Family involvement: Families often act as primary decision-makers, navigating options alongside senior surgical specialists.
  • Multidisciplinary teams: Specialists in nuclear medicine and oncology personalize treatment paths based on tumor pathology.
  • Legal surrogates: Designated proxies or next-of-kin decide for patients unable to communicate their medical wishes.

Bookimed Expert Insight: Data from Fuda Cancer Hospital shows that treating 30,000+ international patients requires bridging different decision-making styles. While Western patients often decide individually, Chinese specialists are accustomed to detailed consultations with the family first. Choosing a JCI-accredited facility ensures that these family-driven discussions still respect international standards for informed patient consent.

Patient Consensus: Patients note that doctors in China may speak directly to relatives before sharing specific details with the patient. It is common for senior surgeons to lead the decision when choosing between aggressive surgery or palliative care.

Get a free consultation

Select the best way to contact you